administration results in high remission rates in adult-onset Still's disease , but the recurrence rate increases on tocilizumab discontinuation, with a longer tocilizumab interval and lowerTocilizumab is effective in reducing systemic inflammation and lowering glucocorticoid doses in patients with AOSD; however, the possibility of tocilizumab withdrawal has not been explored.
The systemic feature score, Pouchot score, and modified Pouchot score were used to evaluate the disease activity.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: